---
schema_version: "secwatch.filing_event.v1"
accession: "0001386570-25-000030"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2025-12-22T23:59:59+00:00"
generated_at: "2026-05-16T12:24:10.663403+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Niagen acquires QUB NR patent portfolio; $1M upfront, annual payments through 2038

## Summary
- One-time ~$1M payment to QUB for accrued royalties through 2024; annual $500K+£35K through 2038.
- Additional one-time payments of $1.5M in 2035 and $2M in 2038 as consideration for patent assignment and release.
- QUB assigned all patent rights to ChromaDex; prior JOMA and License Agreement terminated with royalty obligations released.
- Acquired portfolio includes composition-of-matter patents for NR salt forms (e.g., NR Malate, NR Tartrate) and global rights.
- Niagen now sole owner of core NR IP estate with >90 patents worldwide; CEO cites enhanced control and shareholder protection.

## SEC filing metadata
- accession: 0001386570-25-000030
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2025-12-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000030/0001386570-25-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000138657025000030/cdxc-20251218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001386570-25-000030
- JSON: https://secwatch.observer/filing/0001386570-25-000030.json
- Plain text: https://secwatch.observer/filing/0001386570-25-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.